Spearheaded by dual English-French qualified Denis Schertenleib, who has a background in physics and molecular neurobiology, the team at Schertenleib has a wealth of experience handling complex litigation before the EPO, French courts, and the UPC. The firm has a specific penchant for advising large multinational pharmaceutical companies on their medical patent infringement, validity, and enforcement issues, and the group also handles filings. Marc Lauzeral is also a key name in the team, as well as Ombeline Degrèze-Péchade; both are seasoned litigators with significant pharmaceutical expertise.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Excellent firm, with a great specialisation in IP. Also has understanding of UK/US clients.’
‘Excellent individual lawyers.’
‘The Cabinet Schertenleib team stands out in life sciences and pharmaceutical patent litigation, with an impressive team of experts in this field. Their strength lies in the rare combination of both legal and scientific knowledge, allowing them to handle complex cases more efficiently than other firms.'
'The firm's strong international connections make them ideal for handling complicated cross-border cases. They are definitely the go-to address for pharmaceutical patent litigation in France.’
‘Denis Schertenleib's exceptional scientific background (physics and molecular neurobiology) combined with his extensive legal experience and his negotiating skills, makes him a standout leader in complex, high-stake cases.'
'Ombeline Degrèze-Péchade's strength is a unique combination of scientific expertise and exceptional legal skills as well as her impressive knowledge of regulatory and patent law which makes her an excellent patent litigator and brilliant strategic advisor.'
'‘The most sophisticated patent firm at the French bar.’